German science and technology company Merck KGaA has announced its acquisition of U.S.-based life sciences company Bio-Techne in an all-cash deal valued at $11.3 billion. The acquisition marks Merck’s largest deal in more than a decade and is aimed at expanding its presence in advanced biological research, cell and gene therapy, and precision diagnostics.
The strategic acquisition is expected to strengthen Merck’s Life Science division, which the company sees as a major driver of future growth.
Deal Overview
| Particular | Details |
|---|---|
| Acquiring Company | Merck KGaA (Germany) |
| Target Company | Bio-Techne (USA) |
| Deal Value | $11.3 Billion |
| Offer Price | $73 per share |
| Deal Type | All-cash acquisition |
| Expected Closing | Late 2026 or Early 2027 (subject to approvals) |
Why Is Merck Acquiring Bio-Techne?
Merck aims to strengthen its position in the rapidly growing life sciences market by expanding its portfolio of research tools and laboratory technologies.
The acquisition will help Merck:
- Expand its life sciences business.
- Strengthen capabilities in advanced biological research.
- Increase its presence in cell and gene therapy.
- Enhance precision diagnostics offerings.
- Support pharmaceutical research and drug development.
What Does Bio-Techne Do?
Bio-Techne is a leading supplier of life science research products used by scientists, biotechnology companies, and pharmaceutical manufacturers worldwide.
Its portfolio includes:
- Research reagents
- Proteins
- Antibodies
- Analytical instruments
- Cell and gene therapy technologies
- Laboratory consumables
These products are widely used in drug discovery, biomedical research, and biopharmaceutical manufacturing.
Strategic Importance of the Acquisition
According to Merck, the acquisition will significantly strengthen its position in high-growth scientific fields.
These include:
- Advanced biological research
- Cell therapy
- Gene therapy
- Precision diagnostics
- Drug discovery
- Biopharmaceutical manufacturing
The company estimates these areas represent a market opportunity worth approximately $27 billion.
Financial Highlights
- Deal value: $11.3 billion
- Offer price: $73 per Bio-Techne share
- Approximately 24% premium over Bio-Techne’s previous closing price
- Merck plans to finance the acquisition through a combination of existing cash and new debt.
- The company expects annual cost synergies of around €140 million within three years after the deal closes.
Market Reaction
The announcement received a positive response from investors.
- Bio-Techne shares surged following the acquisition announcement.
- Merck shares also gained as investors viewed the acquisition as strategically important for long-term growth.
- Industry analysts described the acquisition as a strong strategic fit with limited expected regulatory hurdles.
Benefits for Merck
The acquisition is expected to provide several long-term advantages.
Expanded Product Portfolio
Merck will gain access to Bio-Techne’s extensive range of research products and laboratory technologies.
Stronger Position in Life Sciences
The deal reinforces Merck’s Life Science division as a key growth engine.
Growth in Emerging Technologies
The acquisition strengthens Merck’s capabilities in fast-growing areas such as:
- Cell therapy
- Gene therapy
- Multi-omics
- Protein analytics
- Precision medicine
Greater Support for Drug Development
The combined portfolio will help researchers and pharmaceutical companies accelerate drug discovery and development.
Impact on the Pharmaceutical Industry
The acquisition reflects the growing trend of consolidation within the life sciences industry.
It is expected to:
- Increase innovation in laboratory technologies.
- Improve access to advanced research tools.
- Strengthen biopharmaceutical manufacturing capabilities.
- Support future breakthroughs in precision medicine and advanced therapies.
What Happens Next?
The transaction is expected to close in late 2026 or early 2027, subject to shareholder and regulatory approvals. After completion, Bio-Techne will become part of Merck’s Life Science business, further expanding the company’s global footprint in research and biotechnology.
Conclusion
Merck’s $11.3 billion acquisition of Bio-Techne represents one of the most significant life sciences deals in recent years. By combining Bio-Techne’s expertise in research reagents, analytical tools, and advanced biotechnology with Merck’s global presence, the company aims to strengthen its leadership in life sciences, cell and gene therapy, and precision diagnostics. The acquisition also underscores the growing importance of strategic investments in advanced biological research as pharmaceutical innovation continues to accelerate worldwide.
Recommended Products
